These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
123 related articles for article (PubMed ID: 35577251)
1. Minimum inhibitory concentration of cycloserine against Mycobacterium tuberculosis using the MGIT 960 system and a proposed critical concentration. Wu X; Shang Y; Ren W; Wang W; Wang Y; Xue Z; Li S; Pang Y Int J Infect Dis; 2022 Aug; 121():148-151. PubMed ID: 35577251 [TBL] [Abstract][Full Text] [Related]
2. Determination of critical concentration for drug susceptibility testing of Mycobacterium tuberculosis against para-aminosalicylic acid with clinical isolates with thyA, folC and dfrA mutations. Wang W; Li S; Ge Q; Guo H; Shang Y; Ren W; Wang Y; Xue Z; Lu J; Pang Y Ann Clin Microbiol Antimicrob; 2022 Nov; 21(1):48. PubMed ID: 36335391 [TBL] [Abstract][Full Text] [Related]
3. Reevaluating Rifampicin Breakpoint Concentrations for Mycobacterium tuberculosis Isolates with Disputed Wang W; Liu R; Yao C; Huo F; Shang Y; Zhang X; Wang Y; Xue Z; Ma L; Pang Y Microbiol Spectr; 2022 Feb; 10(1):e0208721. PubMed ID: 35107324 [TBL] [Abstract][Full Text] [Related]
4. High clustering rate and genotypic drug-susceptibility screening for the newly recommended anti-tuberculosis drugs among global extensively drug-resistant Trisakul K; Nonghanphithak D; Chaiyachat P; Kaewprasert O; Sakmongkoljit K; Reechaipichitkul W; Chaiprasert A; Blair D; Clark TG; Faksri K Emerg Microbes Infect; 2022 Dec; 11(1):1857-1866. PubMed ID: 35792049 [TBL] [Abstract][Full Text] [Related]
5. Molecular Screening Versus Phenotypic Susceptibility Testing of Multidrug-Resistant Mycobacterium tuberculosis Isolates for Streptomycin and Ethambutol. Al-Mutairi NM; Ahmad S; Mokaddas E Microb Drug Resist; 2018 Sep; 24(7):923-931. PubMed ID: 29336677 [TBL] [Abstract][Full Text] [Related]
6. Strong Increase in Moxifloxacin Resistance Rate among Multidrug-Resistant Mycobacterium tuberculosis Isolates in China, 2007 to 2013. Xia H; Zheng Y; Liu D; Wang S; He W; Zhao B; Song Y; Ou X; Zhou Y; van den Hof S; Cobelens F; Zhao Y Microbiol Spectr; 2021 Dec; 9(3):e0040921. PubMed ID: 34851179 [TBL] [Abstract][Full Text] [Related]
7. Validation of Cycloserine Efficacy in Treatment of Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis in Beijing, China. Yu X; Zeng X; Shi W; Hu Y; Nie W; Chu N; Huang H Antimicrob Agents Chemother; 2018 Mar; 62(3):. PubMed ID: 29311073 [TBL] [Abstract][Full Text] [Related]
9. Genotype-Phenotype Characterization of Serial Mycobacterium tuberculosis Isolates in Bedaquiline-Resistant Tuberculosis. Brown TS; Tang L; Omar SV; Joseph L; Meintjes G; Maartens G; Wasserman S; Shah NS; Farhat MR; Gandhi NR; Ismail N; Brust JCM; Mathema B Clin Infect Dis; 2024 Feb; 78(2):269-276. PubMed ID: 37874928 [TBL] [Abstract][Full Text] [Related]
10. Reevaluation of the critical concentration for drug susceptibility testing of Mycobacterium tuberculosis against pyrazinamide using wild-type MIC distributions and pncA gene sequencing. Werngren J; Sturegård E; Juréen P; Ängeby K; Hoffner S; Schön T Antimicrob Agents Chemother; 2012 Mar; 56(3):1253-7. PubMed ID: 22203587 [TBL] [Abstract][Full Text] [Related]
11. Comparison of Zong Z; Jing W; Shi J; Wen S; Zhang T; Huo F; Shang Y; Liang Q; Huang H; Pang Y Antimicrob Agents Chemother; 2018 Aug; 62(8):. PubMed ID: 29844043 [TBL] [Abstract][Full Text] [Related]
13. Prevalence and genetic basis of Mycobacterium tuberculosis resistance to pretomanid in China. Zhao B; Zheng H; Timm J; Song Z; Pei S; Xing R; Guo Y; Ma L; Li F; Li Q; Li Y; Huang L; Teng C; Wang N; Gupta A; Juneja S; Huang F; Zhao Y; Ou X Ann Clin Microbiol Antimicrob; 2024 May; 23(1):40. PubMed ID: 38702782 [TBL] [Abstract][Full Text] [Related]
14. Performance of Sequencing in Predicting Ofloxacin Resistance in Wang Z; Xie T; Mu C; Sun R; Wang C; Zhao H; Ju H Ann Clin Lab Sci; 2018 Jan; 48(1):69-74. PubMed ID: 29530999 [TBL] [Abstract][Full Text] [Related]
15. Whole-genome sequence analysis and comparisons between drug-resistance mutations and minimum inhibitory concentrations of Mycobacterium tuberculosis isolates causing M/XDR-TB. Nonghanphithak D; Kaewprasert O; Chaiyachat P; Reechaipichitkul W; Chaiprasert A; Faksri K PLoS One; 2020; 15(12):e0244829. PubMed ID: 33382836 [TBL] [Abstract][Full Text] [Related]
16. Prognostic significance of novel Valafar F; Ramirez-Busby SM; Torres J; Paul LV; Rodwell TC; Victor TC; Rodrigues C; Gler MT; Crudu V; Catanzaro T Int J Mycobacteriol; 2015 Mar; 4(Suppl 1):51-52. PubMed ID: 27695670 [TBL] [Abstract][Full Text] [Related]
17. Meropenem-clavulanate has high in vitro activity against multidrug-resistant Mycobacterium tuberculosis. Davies Forsman L; Giske CG; Bruchfeld J; Schön T; Juréen P; Ängeby K Int J Mycobacteriol; 2015 Mar; 4 Suppl 1():80-1. PubMed ID: 27128620 [TBL] [Abstract][Full Text] [Related]
18. Discordance across Phenotypic and Molecular Methods for Drug Susceptibility Testing of Drug-Resistant Mycobacterium tuberculosis Isolates in a Low TB Incidence Country. Ahmad S; Mokaddas E; Al-Mutairi N; Eldeen HS; Mohammadi S PLoS One; 2016; 11(4):e0153563. PubMed ID: 27096759 [TBL] [Abstract][Full Text] [Related]
20. [A preliminary study on the molecular characteristics of D-cycloserine resistance of Li C; Li GL; Luo Q; Li SJ; Wang RB; Lou YL; Lyu JX; Wan KL Zhonghua Liu Xing Bing Xue Za Zhi; 2017 Feb; 38(2):240-243. PubMed ID: 28231674 [No Abstract] [Full Text] [Related] [Next] [New Search]